Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression

Signal transducers and activators of transcription (STAT) 1 plays a pivotal role in cell‐cycle and cell‐fate determination, and vascular endothelial growth factor (VEGF) also contributes tumor growth. Recently, interferon (IFN) α has been reported to be effective for prevention of hepatocellular carcinomas (HCCs) recurrence, but the detailed mechanisms remain elusive. In vitro, cobalt chloride–treated VEGF induction and hypoxia responsive element (HRE) promoter activity were inhibited by IFNs and this abrogation was cancelled by introduction of small interfering RNA for STAT1. Immunoprecipitation/chromatin immunoprecipitation analyses showed STAT1 bound to hypoxia‐inducible factor (HIF)‐1α and dissociated HIF‐complex from HRE promoter lesion. In a xenograft model using Balb/c nude mice, tumor growth was suppressed by IFNα through inhibition of VEGF expression and it was oppositely enhanced when STAT1‐deleted cells were injected. This augmentation was due to upregulation of VEGF and hyaluronan synthase 2. In human samples, 29 HCCs were resected, divided into two groups based on STAT1 activation in tumor and the clinical features were investigated. Patients with suppressed STAT1 activity had a shorter recurrence‐free survival. Histological and reverse transcriptase‐polymerase chain reaction (RT‐PCR) analyses showed portal vein microinvasion and increased VEGF levels in tumors from suppressed STAT1 group. These human samples also showed a reverse correlation between VEGF and STAT1‐regulated genes expression. These results in vitro and in vivo suggested that IFNα are potential candidates for prevention of vessel invasion acting through inhibition of VEGF expression and need to be properly used when STAT1 expression is suppressed.

[1]  Qi Zheng,et al.  Association of Genetic Polymorphisms in STAT1 Gene with Increased Risk of Hepatocellular Carcinoma , 2010, Oncology.

[2]  H. Nagano Treatment of Advanced Hepatocellular Carcinoma: Intraarterial Infusion Chemotherapy Combined with Interferon , 2010, Oncology.

[3]  L. Hennighausen,et al.  Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation , 2009, The Journal of experimental medicine.

[4]  L. Hennighausen,et al.  Genomic dissection of the cytokine-controlled STAT5 signaling network in liver. , 2008, Physiological genomics.

[5]  L. Hennighausen,et al.  Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration , 2007, Hepatology.

[6]  P. Borrow,et al.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage , 2007, The Journal of experimental medicine.

[7]  S. Nilsson,et al.  The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. , 2005, Experimental cell research.

[8]  Jung Weon Lee,et al.  The FASEB Journal express article 10.1096/fj.04-3099fje. Published online May 26, 2005. ©2005 FASEB , 2022 .

[9]  D. Häussinger,et al.  Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. , 2004, Journal of hepatology.

[10]  A. Onitsuka,et al.  Rapid growth of hepatocellular carcinoma after or during interferon treatment for chronic hepatitis C: Report of three cases , 1996, Surgery Today.

[11]  N. Hayashi,et al.  Hepatitis C Virus Core Protein Differently Regulates the JAK-STAT Signaling Pathway under Interleukin-6 and Interferon-γ Stimuli* , 2003, Journal of Biological Chemistry.

[12]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[13]  N. Hayashi,et al.  Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. , 2003, The Journal of biological chemistry.

[14]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[15]  S. Fan,et al.  Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study , 2001, Annals of surgery.

[16]  C. Frelin,et al.  Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. , 1998, The Journal of biological chemistry.

[17]  M. Kojiro,et al.  Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines , 1999, Hepatology.

[18]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[19]  Y. Sun,et al.  Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. , 1998, Journal of immunology.

[20]  S. Arii,et al.  Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor , 1996, Hepatology.

[21]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[22]  C. Bucana,et al.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Darnell,et al.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions , 1994, Cell.

[24]  J. Bogdanowicz,et al.  REPORT OF THREE CASES. , 1963, American journal of diseases of children.